Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHA:603707)
China
· Delayed Price · Currency is CNY 9.69
0.00 (0.00%)
At close: Mar 9, 2026
SHA:603707 Revenue
Nanjing King-Friend Biochemical Pharmaceutical had revenue of 945.90M CNY in the quarter ending September 30, 2025, with 0.06% growth. This brings the company's revenue in the last twelve months to 3.76B, down -3.00% year-over-year. In the year 2024, Nanjing King-Friend Biochemical Pharmaceutical had annual revenue of 3.92B, down -0.20%.
Revenue (ttm)
3.76B
Revenue Growth
-3.00%
P/S Ratio
4.16
Revenue / Employee
2.77M
Employees
1,360
Market Cap
15.66B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.92B | -7.80M | -0.20% |
| Dec 31, 2023 | 3.93B | 218.67M | 5.89% |
| Dec 31, 2022 | 3.71B | 26.03M | 0.71% |
| Dec 31, 2021 | 3.69B | 771.81M | 26.48% |
| Dec 31, 2020 | 2.91B | 445.21M | 18.03% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| China Resources Jiangzhong Pharmaceutical Co.,Ltd | 4.24B |
| Shenzhen Kangtai Biological Products | 2.70B |
| Guangdong Zhongsheng Pharmaceutical | 2.45B |
| Shenzhen Hepalink Pharmaceutical Group | 5.38B |
| Hybio Pharmaceutical | 898.10M |
| Zhejiang Jiuzhou Pharmaceutical | 5.36B |
| Guobang Pharma | 5.94B |
| Shanghai Shyndec Pharmaceutical | 9.36B |